Status:
UNKNOWN
Host Response Mediators in Coronavirus (COVID-19) Infection
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
British Columbia Centre for Disease Control
Conditions:
COVID-19
SARS-CoV2
Eligibility:
All Genders
18+ years
Brief Summary
The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortal...
Detailed Description
Purpose: To determine whether angiotensin II receptor blockers (ARBs) decrease severity or mortality in hospitalized COVID-19 infected adults. Main Hypothesis: Modulation of ACE2 by ARBs decreases th...
Eligibility Criteria
Inclusion
- Individuals over 18 years of age who have confirmed COVID-19 infection (according to local hospital or provincial laboratories clinically approved laboratory testing for COVID-19).
Exclusion
- None
Key Trial Info
Start Date :
March 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04510623
Start Date
March 17 2020
End Date
June 30 2022
Last Update
August 12 2020
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary - Foothills
Calgary, Alberta, Canada
2
Stollery Children's Hospital
Edmonton, Alberta, Canada
3
University of Alberta
Edmonton, Alberta, Canada
4
Surrey Memorial Hospital
Surrey, British Columbia, Canada